Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: Results from a randomized, open-label, phase III trial

by on 2 de maig de 2023 with No hi ha comentaris
  • Tempero, M. A., Pelzer, U., O’Reilly, E. M., Winter, J., Oh, D. -., Li, C. -., Tabernero, J., . . . APACT Investigators. (2023). Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: Results from a randomized, open-label, phase III trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 41(11), 2007-2019. https://doi.org/10.1200/JCO.22.01134

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *